Vectorious Medical Technologies develops novel treatment for heart failure patients which is based on physician directed, patients’ self-management paradigm. Leveraging its advanced, first of its kind, implantable V-LAP platform, which harvests valuable information from the heart’s left atrium, physicians and patients can monitor and manage disease status, prevent hospitalizations and improve quality of life. The V-LAP system is an investigational device which is currently under evaluation in multiple clinical studies in Europe, Israel and the U.S.
Looking for a particular Vectorious Medical Technologies employee's phone or email?
The Vectorious Medical Technologies annual revenue was $6 million in 2026.
Eyal Orion is the Co-Founder, CEO of Vectorious Medical Technologies.
86 people are employed at Vectorious Medical Technologies.
The NAICS codes for Vectorious Medical Technologies are [33, 334].
The SIC codes for Vectorious Medical Technologies are [38, 384].